Loading stock data…
BBNX
$9.63-0.19 (-1.93%)
Market ClosedLast close May 13
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Beta Bionics, Inc. in the Healthcare sector is trading at $9.63. Wall Street consensus targets $20.27 (11 analysts), implying a +110.5% move over the next 12 months. The stock is currently near its 52-week low of $8.80, remaining 49.3% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 28 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +110.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 28) — potential for technical mean-reversion
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$9.63
Potential Downside
0%
Whystock Fair Value$9.63
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Mean target$20.27+110.5%
Range$14.00 – $32.00
Fundamentals
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$504.88M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-25.51%
Volume
Today's trading volume
755,601
Recent News
Beta Bionics Touts Pharmacy Push, iLet Momentum and 2027 Mint Patch Pump Plans
Beta Bionics (NASDAQ:BBNX) Chief Financial Officer Stephen Feider said the company’s first-quarter outperformance was supported by increasing use of the pharmacy reimbursement channel, expanded sales coverage and growing confidence in the company’s iLet insulin pump platform. Speaking at a Bank of
Here's Why We're Not Too Worried About Beta Bionics' (NASDAQ:BBNX) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Beta Bionics, Inc. Q1 2026 Earnings Call Summary
Moby summary of Beta Bionics, Inc.'s Q1 2026 earnings call
Beta Bionics Inc (BBNX) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amid Operational ...
Beta Bionics Inc (BBNX) reports a 57% increase in net sales and raises full-year guidance despite facing FDA challenges and competitive pressures.
Beta Bionics Q1 Earnings Call Highlights
Beta Bionics (NASDAQ:BBNX) reported first-quarter 2026 net sales of $27.6 million, up 57% year-over-year, as management cited growth in new patient starts, a rising base of recurring pharmacy users, and continued expansion of pharmacy channel access for its iLet insulin delivery system. Quarterly r